MicroRNA signatures from multidrug‑resistant Mycobacterium tuberculosis
- PMID: 26324150
- PMCID: PMC4626138
- DOI: 10.3892/mmr.2015.4262
MicroRNA signatures from multidrug‑resistant Mycobacterium tuberculosis
Abstract
Tuberculosis (TB) infections, caused by multidrug‑resistant Mycobacterium tuberculosis (MDR MTB), remain a significant public health concern worldwide. The regulatory mechanisms underlying the emergence of MDR MTB strains remain to be fully elucidated, and further investigation is required in order to develop better strategies for TB control. The present study investigated the expression profile of microRNA (miRNA) in MTB strains, and examined the differences between sensitive MTB and MDR MTB using next generation sequencing (NGS) with Illumina Deep Sequencing technology to better understand the mechanisms of resistance in MDR MTB, A total of 5, 785 and 195, and 6, 290 and 595 qualified Illumina reads were obtained from two MDR MTB strains, and 6, 673 and 665, and 7, 210 and 217 qualified Illumina reads were obtained from two sensitive MTB strains. The overall de novo assembly of miRNA sequence data generated 62 and 62, and 95 and 112 miRNAs between the 18 and 30 bp long from sensitive MTB strains and MDR MTB strains, respectively. Comparative miRNA analysis revealed that 142 miRNAs were differentially expressed in the MDR MTB strain, compared with the sensitive MTB strain, of which 48 were upregulated and 94 were downregulated. There were six similarly expressed miRNAs between the MDR and sensitive MTB strains, and 108 miRNAs were expressed only in the MDR MTB strain. The present study acquired miRNA data from sensitive MTB and MDR MTB strains using NGS techniques, and this identification miRNAs may serve as an invaluable resource for revealing the molecular basis of the regulation of expression associated with the mechanism of drug‑resistance in MTB.
Figures





Similar articles
-
First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance.BMC Microbiol. 2010 Mar 17;10:82. doi: 10.1186/1471-2180-10-82. BMC Microbiol. 2010. PMID: 20236539 Free PMC article.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.J Antimicrob Chemother. 2008 Oct;62(4):713-9. doi: 10.1093/jac/dkn269. Epub 2008 Jun 27. J Antimicrob Chemother. 2008. PMID: 18587134
-
[Future prospects of molecular epidemiology in tuberculosis].Kekkaku. 2009 Dec;84(12):783-4. Kekkaku. 2009. PMID: 20077862 Japanese.
-
Exploring functional genomics for the development of novel intervention strategies against tuberculosis.Int J Med Microbiol. 2007 Nov;297(7-8):559-67. doi: 10.1016/j.ijmm.2007.03.003. Epub 2007 Apr 27. Int J Med Microbiol. 2007. PMID: 17467338 Review.
Cited by
-
Role of Small Non-Coding RNA in Gram-Negative Bacteria: New Insights and Comprehensive Review of Mechanisms, Functions, and Potential Applications.Mol Biotechnol. 2025 Aug;67(8):2978-2996. doi: 10.1007/s12033-024-01248-w. Epub 2024 Aug 17. Mol Biotechnol. 2025. PMID: 39153013 Review.
-
Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Nat Rev Genet. 2016 May;17(5):257-71. doi: 10.1038/nrg.2016.10. Epub 2016 Mar 21. Nat Rev Genet. 2016. PMID: 26996076 Free PMC article. Review.
-
Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO Mol Med. 2022 Dec 7;14(12):e14088. doi: 10.15252/emmm.202114088. Epub 2022 Oct 31. EMBO Mol Med. 2022. PMID: 36314872 Free PMC article. Review.
-
Tuberculosis Biomarkers: From Diagnosis to Protection.Infect Dis Rep. 2016 Jun 24;8(2):6568. doi: 10.4081/idr.2016.6568. eCollection 2016 Jun 24. Infect Dis Rep. 2016. PMID: 27403267 Free PMC article. Review.
-
Identification and Characterization of miRNAs in Response to Leishmania donovani Infection: Delineation of Their Roles in Macrophage Dysfunction.Front Microbiol. 2017 Mar 2;8:314. doi: 10.3389/fmicb.2017.00314. eCollection 2017. Front Microbiol. 2017. PMID: 28303124 Free PMC article.
References
-
- World Health Organization (WHO) Global Tuberculosis Control Report 2010. WHO; Geneva: 2010.
-
- US Agency for International Development Report to congress: Health-related research and development activities at USAID-an update on the five-year strategy, 2006–2010. US Agency for International Development. 2009;182:1788–1790.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources